trovagene.investorroom.com
Trovagene Investor Relations - Events
http://trovagene.investorroom.com/events
Get News Alerts by Email. No events to display. The use of Trovagene’s urine (or blood) liquid biopsy is only intended for detection and monitoring of mutations in patients previously diagnosed with cancer. It is not intended for screening of asymptomatic patients to diagnose cancer. Senior Management and Board of Directors.
trovagene.investorroom.com
Trovagene Investor Relations - Investor Relations
http://trovagene.investorroom.com/2015-08-10-Trovagene-Inc-Announces-Second-Quarter-2015-Financial-Results
Welcome to Trovagene Investor Relations. Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring (PCM) technology for the detection and monitoring of circulating tumor DNA (ctDNA) in urine and blood. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s PCM technology is designed to provide important clinical information beyond the current standard. Nov 9, 2016. Nov 7, 2016.
trovagene.investorroom.com
Trovagene Schedules Release of Second Quarter 2015 Financial Results and Investor Conference Call - Jul 23, 2015
http://trovagene.investorroom.com/2015-07-23-Trovagene-Schedules-Release-of-Second-Quarter-2015-Financial-Results-and-Investor-Conference-Call
Trovagene Schedules Release of Second Quarter 2015 Financial Results and Investor Conference Call. Jul 23, 2015. July 23, 2015 (5:15am). July 23, 2015 / PRNewswire. Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the second quarter and the six months ended June 30, 2015. On Monday, August 10, 2015. At 4:00 pm Eastern Daylight Time. 1:00 pm Pacific Daylight Time. At 5:00 pm Eastern Daylight Time. About Trovagene, Inc.
trovagene.investorroom.com
Trovagene Investor Relations - Stock Information
http://trovagene.investorroom.com/stock-price
Stock information is for historical and informational purposes, and is not intended for trading. Quote data delayed by at least 15 minutes. The use of Trovagene’s urine (or blood) liquid biopsy is only intended for detection and monitoring of mutations in patients previously diagnosed with cancer. It is not intended for screening of asymptomatic patients to diagnose cancer. Senior Management and Board of Directors.
trovagene.investorroom.com
Trovagene Investor Relations - Investor Alerts
http://trovagene.investorroom.com/investor-alerts
Sign up to receive our news releases, SEC Filings, Stock Price changes, etc. via email. The release will come to your email as body text within the message. You may unsubscribe at any time. If you use an RSS Reader, you may add our site update feed to your reader to receive updates. You may unsubscribe at any time. Senior Management and Board of Directors.
trovagene.investorroom.com
Trovagene Investor Relations - Press Releases
http://trovagene.investorroom.com/press-releases
Get News Alerts by Email. Nov 9, 2016. Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments. Nov 7, 2016. Trovagene Announces HPV Patent Issuance by U.S. Patent and Trademark Office, Broadening Its Precision Cancer Monitoring IP Portfolio. Nov 2, 2016. Trovagene Schedules Release of Third Quarter 2016 Financial Results and Investor Conference Call. Oct 17, 2016. Trovagene to Present at the BIO Investor Forum in San Francisco on October 19. Oct 4, 2016.
bergcapitalmarkets.com
: Berg Capital Markets
http://www.bergcapitalmarkets.com/clients
UltraMedia, Inc. - Designers of Interior Technology. 2013 Berg Capital Markets LLC.
SOCIAL ENGAGEMENT